^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    clonoSEQ®

    Company:
    Adaptive Biotech
    1d
    Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation (clinicaltrials.gov)
    P2, N=9, Active, not recruiting, City of Hope Medical Center | Recruiting --> Active, not recruiting | N=20 --> 9
    Enrollment closed • Enrollment change
    |
    clonoSEQ®
    |
    Opdivo (nivolumab) • Imbruvica (ibrutinib) • cyclophosphamide • Breyanzi (lisocabtagene maraleucel) • fludarabine IV
    1d
    Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acute Lymphoblastic Leukemia With a Genetic Change Requiring More Treatment (clinicaltrials.gov)
    P2, N=90, Not yet recruiting, SWOG Cancer Research Network
    New P2 trial
    |
    CD19 (CD19 Molecule) • KMT2A (Lysine Methyltransferase 2A)
    |
    clonoSEQ®
    |
    cytarabine • doxorubicin hydrochloride • cyclophosphamide • Blincyto (blinatumomab) • methotrexate • vincristine • daunorubicin • Revuforj (revumenib) • leucovorin calcium • mercaptopurine • Asparlas (calaspargase pegol-mknl) • thioguanine • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate)
    7d
    Determination 2 - Isatuximab, Iberdomide, Bortezomib and Dexamethasone Induction, Followed by Risk- and Response-Adapted Consolidation and Maintenance Therapy, in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma (clinicaltrials.gov)
    P3, N=720, Not yet recruiting, Dana-Farber Cancer Institute
    New P3 trial
    |
    TP53 (Tumor protein P53)
    |
    clonoSEQ®
    |
    bortezomib • dexamethasone • iberdomide (CC-220) • Lynozyfic (linvoseltamab-gcpt) • Sarclisa subcutaneous (isatuximab subcutaneous) • captisol-enabled melphalan
    9d
    COMMANDER: COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide (clinicaltrials.gov)
    P1/2, N=80, Active, not recruiting, University of Alabama at Birmingham | Trial completion date: Oct 2026 --> Aug 2028 | Trial primary completion date: Apr 2026 --> Aug 2028
    Trial completion date • Trial primary completion date • Minimal residual disease
    |
    clonoSEQ®
    |
    Darzalex (daratumumab) • carfilzomib • dexamethasone • iberdomide (CC-220)
    9d
    TrAVeRse: A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma (clinicaltrials.gov)
    P2, N=108, Active, not recruiting, AstraZeneca | Trial primary completion date: Jul 2028 --> Oct 2028 | Trial completion date: Jul 2028 --> Oct 2028
    Trial completion date • Trial primary completion date
    |
    TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • CCND1 (Cyclin D1) • PAX5 (Paired Box 5) • CD5 (CD5 Molecule)
    |
    Chr t(11;14)
    |
    clonoSEQ®
    |
    Venclexta (venetoclax) • Rituxan (rituximab) • Calquence (acalabrutinib)
    13d
    At ASCO and EHA 2026, New Data Reinforce the Pivotal Role of clonoSEQ® MRD Testing Across Hematology Clinical Practice and Research (Adaptive Biotechnologies Press Release)
    "Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced that its next-generation sequencing (NGS)-based clonoSEQ® test for measurable residual disease (MRD) assessment will be included in 33 presentations, including one plenary session and 14 oral presentations, across the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29-June 3 in Chicago, and the European Hematology Association (EHA) Congress, taking place June 11-14 in Stockholm."
    Clinical data
    |
    clonoSEQ®
    21d
    A Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Combination With Low Intensity Chemotherapy in Older Patients With Newly Diagnosed B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P2, N=3, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting | N=60 --> 3
    Enrollment closed • Enrollment change
    |
    clonoSEQ®
    |
    cytarabine
    27d
    Horizon Two Adaptive Platform Study in High Risk Newly Diagnosed Multiple Myeloma (clinicaltrials.gov)
    P2, N=300, Recruiting, Multiple Myeloma Research Consortium | Not yet recruiting --> Recruiting | Initiation date: Oct 2025 --> Apr 2026
    Enrollment open • Trial initiation date
    |
    SDC1 (Syndecan 1)
    |
    TP53 mutation
    |
    clonoSEQ®
    |
    Sarclisa (isatuximab-irfc) • Lynozyfic (linvoseltamab-gcpt)
    29d
    Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (clinicaltrials.gov)
    P2, N=35, Not yet recruiting, City of Hope Medical Center
    New P2 trial
    |
    clonoSEQ®
    |
    Venclexta (venetoclax) • Calquence (acalabrutinib) • Monjuvi (tafasitamab-cxix)
    30d
    DUAL TARGETED LENTIVIRAL TRANSDUCED ANTI-CD20/ANTI-CD19 (LV20.19) CAR T CELLS FOR RELAPSED, REFRACTORY CLL (EHA 2026)
    P1/2 | "While CD19 CAR T-cell therapy (lisocabtagene maraleucel) was approved for CLL pts exposed to BTKi/BCL2i, the complete response (CR) rate was 18% and the median PFS was 11.9 months in the pivotal phase II trial. Dual targeted LV20.19 CAR T cell therapy resulted in high CR/CRi rate and encouraging PFS compared to currently available single targeted CARs in BTKi/BCL2i exposed CLL. Interestingly, dual targeting of CD19 and CD20 in CLL resulted in a high rate of IEC-HS, a phenomena that was IL-6 independent, and occurred at rates higher than seen with other B-cell histologies in this trial. With a lower dose of 1e6 cells/kg, responses were maintained with an improved safety profile."
    CAR T-Cell Therapy
    |
    PD-L1 (Programmed death ligand 1) • IFNG (Interferon, gamma) • IL6 (Interleukin 6) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • IL2 (Interleukin 2) • IL10 (Interleukin 10) • IL1R1 (Interleukin 1 receptor, type I) • IL33 (Interleukin 33)
    |
    clonoSEQ®
    |
    Breyanzi (lisocabtagene maraleucel) • CAR-20/19-T Cells
    1m
    Tafasitamab and Zanubrutinib for the Treatment of Patients With Newly Diagnosed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, TaZA CLL Study (clinicaltrials.gov)
    P2, N=26, Active, not recruiting, City of Hope Medical Center | Trial completion date: Apr 2026 --> Sep 2026 | Trial primary completion date: Apr 2026 --> Sep 2026
    Trial completion date • Trial primary completion date
    |
    clonoSEQ®
    |
    Brukinsa (zanubrutinib) • Monjuvi (tafasitamab-cxix)
    1m
    DC/MM Fusion Vaccine With BCMA CAR-T in R/R MM (clinicaltrials.gov)
    P1, N=25, Recruiting, David Avigan | Initiation date: Jul 2026 --> Jan 2026 | Not yet recruiting --> Recruiting
    Enrollment open • Trial initiation date
    |
    CSF2 (Colony stimulating factor 2)
    |
    clonoSEQ®